NYSE:FLRConstruction
How Index Additions and Pharma Feasibility Work Could Reshape Fluor’s (FLR) Investment Narrative
In late June 2026, Fluor Corporation (NYSE: FLR) was added to multiple Russell growth benchmarks and the Russell 2000 Growth-Defensive Index, while Voyageur Pharmaceuticals announced it had engaged Fluor to conduct feasibility studies for an iodine project with Bayer and an integrated contrast media manufacturing facility in North America.
These developments highlight Fluor’s growing visibility in key equity benchmarks and its expanding role in complex pharmaceutical supply chain...